Medical treatment of supraesophageal complications of gastroesophageal reflux disease. Am J Med 2001 Dec 03;111 Suppl 8A:197S-201S
Date
12/26/2001Pubmed ID
11749950DOI
10.1016/s0002-9343(01)00830-0Scopus ID
2-s2.0-0035803971 (requires institutional sign-in at Scopus site) 24 CitationsAbstract
A growing number of bronchopulmonary, laryngopharyngeal, and oral cavity disorders are suspected of being caused by gastroesophageal refluxate traveling from the esophageal body. Although diagnostic methods have not been developed to positively identify the etiology of these conditions as being related to refluxate, many patients with these supraesophageal manifestations of gastroesophageal reflux disease (SeGERD) respond to empiric antireflux therapy with proton pump inhibitors (PPIs). When used in an appropriate dose (twice daily) and for an appropriate duration (12 weeks or longer), PPIs can be effective in relieving SeGERD symptoms. Economic issues and outcome studies are needed to help further define the role of PPIs in SeGERD.
Author List
Hogan WJ, Shaker RAuthor
Reza Shaker MD Assoc Provost, Sr Assoc Dean, Ctr Dir, Chief, Prof in the Medicine department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
Gastroesophageal RefluxHumans
Laryngeal Diseases
Long-Term Care
Lung Diseases
Mouth Diseases
Prognosis
Treatment Outcome